Oesophageal candidiasis and squamous cell cancer in patients with gain-of-function STAT1 gene mutation

Abstract

Background

Oesophageal candidiasis is a common, usually self-limiting opportunistic infection, but long-term infection with Candida is known to predispose to oral and oesophageal squamous cell cancer (SCC). Permissive factors that lead to immune deficiencies can underlie persistent or recurring candidiasis, called chronic mucocutaneous candidiasis (CMC). Secondary immune deficiencies are most often due to human immunodeficiency virus (HIV) infection, antibiotic use and immunosuppressive treatment (steroids, chemotherapy). Inborn errors of the immune system (primary immune deficiencies) can present with isolated CMC known as CMC disease (CMCD), which is most often found in patients with autoimmune polyendocrinopathy syndrome type 1 (APS1)/APECED or in patients with an underlying gain-of-function STAT1 mutation (GOF-STAT1).

Objective

To describe a new form of inherited/familial CMC with a high risk for developing squamous cell carcinoma of the oesophagus, due to a gain-of-function mutation in the STAT1 gene.

Methods and results

This report describes a family of patients with CMC with confirmed GOF-STAT1 mutation. These patients usually present with CMCD in childhood, have severe oral and oesophageal candidiasis accompanied by severe difficulty swallowing, chest pain, heartburn, and are at risk of developing oral and/or oesophageal SCC. This case series describes six patients in three generations of the same family, two of whom developed and died of SCC. We recommend regular endoscopic surveillance to detect early oesophageal neoplasia in patients with CMCD as well as urgent endoscopy in symptomatic patients.

Conclusion

CMC is not a well-recognised condition in gastroenterology practice and clinicians need to be aware of the genetics of the condition as well as the risk for oesophageal cancer so that they can counsel their patients and arrange surveillance appropriately.

Keywords

Chronic mucocutaneous candidiasis gain-of-function STAT1 mutation squamous cell carcinoma primary immune deficiency

Introduction

Candida is an opportunistic yeast, colonising gastrointestinal and urogenital mucosa in about 30–50% of healthy humans without causing infection. Candida overgrowth requires permissive circumstances which occur when the immune system is damaged, leading to either primary or secondary immune deficiencies, which, depending on the underlying immune defect, will lead to infections of the skin, nails and mucosa (oral, oesophageal, genital) with Candida, coined chronic mucocutaneous candidiasis (CMC), or to invasive disease (sepsis) with internal organ involvement. Secondary CMC can be precipitated by a range of factors, the most common being secondary immune deficiency caused by human immunodeficiency virus (HIV) infection, when CD4 T lymphocyte counts fall to <100 cells/μl, precipitating acquired immune deficiency syndrome (AIDS). Other frequent precipitating factors include use of antibiotics and immunosuppressive drugs such as long-term systemic or inhaled corticosteroids, chemotherapy for malignancies, as well as other diseases such as diabetes or local factors such as dentures.¹

In contrast to the above, in patients with inborn (genetic) errors of the immune system known as primary immune deficiencies (PIDs), CMC can present as a syndrome with chronic, persistent or recurrent, debilitating Candida infection of the skin, nails and mucous membranes without an obvious cause as defined above (see Figures 2 and 3) In these patients, CMC, especially oral Candida infection (thrush), may occur either in isolation (CMC disease – CMCD), as part of well-defined PID syndromes or part of a broad, severe immune deficiency. Patients with the autosomal dominant (AD) hyper IgE syndrome (HIES) suffer with CMC as well as severe skin and pulmonary staphylococcal infections. This is caused by a mutation in the signal transducer and activator of transcription 3 (STAT3) gene resulting in a faulty STAT3 function, leading to significantly reduced levels of CD4 T helper (Th)-17 cells and circulating interleukin (IL)-17 and IL-22 cytokines. CMC can also be part of a complex clinical phenotype caused by severe immune deficiencies affecting T lymphocytes, where patients suffer with susceptibility to a broad range of microorganisms rather than selective fungal infections. Accumulating evidence suggests that mucocutaneous fungal infections accompany a variety of defects that disrupt the Th-17 pathway,² while protection against invasive disease is mediated by phagocytes, and indeed CMC patients rarely if ever develop invasive fungal disease.¹

Oesophageal candidiasis can present as dysphagia, odynophagia, retrosternal chest pain, or can be an incidental finding at endoscopy. Its typical endoscopic appearance is of white plaques which persist despite water flushes. Oesophageal brushings and biopsy show the characteristic appearance of yeasts and pseudo hyphae. The most common organism associated with this is Candida albicans, although other strains such as C. glabarata and C. tropicalis are increasingly being isolated. Common endoscopic findings associated with oesophageal candidiasis include oesophageal ulcer, gastric ulcer and severe atrophic gastritis.³ Rare complications include ulceration, haemorrhage or oesophageal obstruction from stricture or fistulation to bronchial tree.⁴ For most patients one course of antifungal treatment is sufficient to resolve the problem, and repeat gastroscopy is very rarely needed.

In rare patients with an underlying PID, the oesophageal candidiasis presents as CMCD with recurrent or persistent thrush despite multiple courses of antifungal treatment; it is usually accompanied by candidiasis of the skin, nails and other mucous membranes, and often presents in early childhood and frequently involves multiple family members.

CMCD is known to be caused by at least five different mutations affecting the IL-17 pathways,² but the two most common causes of CMCD are autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED), also known as autoimmune polyendocrinopathy syndrome type 1 (APS1), and AD gain-of-function (GOF) gene mutation of the signalling protein STAT1 (signal transducer and activator of transcription 1).

In APECED/APS1, CMC is seen in >95% of patients, often as the first presenting symptom of disease, followed by the development of a triad of hypoparathyroidism, adrenal and gonadal failure, as well as other endocrine organ involvement (e.g. diabetes). APECED is caused by an inborn error (mutation) of the AIRE gene, inherited in an autosomal recessive manner. AIRE is a transcription factor that promotes the ectopic presentation of self-antigens in the thymic medulla, ensuring removal of self-reactive T lymphocytes in the process of thymic T cell maturation. Defective AIRE function and failed removal of auto-reactive T cells results in autoimmunity, causing endocrine organ failure; however, why these patients develop CMC was a mystery until we and others demonstrated in APECED/APS1 patients the production of neutralising autoantibodies to Th-17 cytokines IL-17A-F and IL-22,^5,6 disrupting Th-17 mediated fungal immunity, which explained why these patients develop CMC in the context of the underlying autoimmunity.

In the other largest group of patients with CMCD, we and others recently identified a GOF mutation in the STAT1 gene as the underlying cause.^7,8 Although the pathogenic mechanisms are still not fully understood, it is thought that the genetic defect results in exaggerated Th1 responses which down regulate STAT3/Th17 immunity, leading to reduced production of IL-17 and IL-22.⁹ In these patients, there have been sporadic reports of a link between CMC and oesophageal squamous cell carcinoma,¹⁰ confirmed in a recent international review of these rare patients.¹¹ In view of the increasingly recognised association of SCC and GOF-STAT1-CMC, we present a case series in a family of three generations with this disease (Figure 1).

Figure 1.

Family tree of CMC patients.

Figure 2.

Appearance of the nails in CMC.

Figure 3.

Appearance of the tongue in CMC.

Case series

Our index patient (pt 1) was a mother of five children. She had suffered since childhood with severe CMCD presenting as oral, oesophageal and genital candidiasis and multiple, severe nail involvement as well as gastroesophageal reflux and difficulty swallowing, hypothyroidism, keratitis, blepharitis, conjunctivitis, styes, eczema, skin abscesses/boils and dental loss. At 58 years of age, she developed oral squamous cell cancer (SCC) which was treated with surgery and radiotherapy but lead to her death 3 years later.

Of her five children, three had CMCD. The eldest was a son (pt 2) who presented in childhood with severe CMCD, recurring lung disease with bronchiectasis, chronic obstructive pulmonary disease (COPD) and widespread eczema, skin infections, abscesses and boils. As an adult, he had intermittent oral thrush which was treated with anti-fungals (Figure 2). He also suffered with indigestion, dysphagia and odynophagia which responded well to proton pump inhibitors. At the age of 40 he had a gastroscopy for persistent symptoms which revealed marked oesophageal candidiasis as well as widespread oesophageal squamous cell carcinoma. Immunosuppressive chemotherapy was avoided in view of his underlying PID and instead he received palliative radiotherapy for extensive bony metastases, but passed away 6 months after diagnosis. The second sibling was his sister (pt 3) aged 34, who presented with chronic oral thrush since childhood which was treated with daily antifungals but nevertheless went on to developed severe dysphagia. Gastroscopy revealed stricturing of the oesophagus and the procedure was abandoned due to poor tolerance. She declined further investigations or surveillance. The third sibling (pt 4), who also had CMCD since childhood, was a younger brother aged 32, with intermittent oral thrush who underwent an initial gastroscopy at 25 years old, which revealed erosive oesophagitis. A repeat surveillance gastroscopy 7 years later was normal, with oesophageal biopsies showing mild oesophagitis with no dysplasia or candidiasis.

In the third generation, of the three children of the eldest brother, two have inherited this mutation and illness. The eldest daughter (pt 5), aged 21, has severe CMCD, bronchiectasis, and suffers with severe dysphagia, heartburn and chest pain. Although the initial gastroscopy was normal, a repeat endoscopy a year later for progressive symptoms although macroscopically normal revealed the presence of chronic inflammation without dysplasia at histology. The younger daughter (pt 6) aged 12 years, developed oral candidiasis aged 3, which perseveres intermittently. Clinical findings including other infections and autoimmune features are presented in Table 1. Immunological work-up for these patients is summarised in Table 2 which demonstrates that routine immunological findings are generally normal. However, specialised tests assessing STAT1 function by measuring STAT1 activity following stimulation with interferons either by assessing phosphorylated STAT1 (pSTAT1) using flow-cytometry or by measuring STAT1-dependent gene transcription using quantitative real-time polymerase chain reaction (qRT-PCR), described in Zheng et al.,⁹ confirmed STAT1 hyperactivity. For patients 1–5 this was previously reported,¹² while findings for patient 6 are shown in Figure 4. All our patients had a heterozygous A267V mutation (c.800C > T p.Ala267Val) in the coiled-coiled (CC) domain of the STAT1 gene. Patients 1–4 were the first patients in whom this GOF-STAT1 mutation was found by targeted sequencing and reported.⁷ The remaining two family members (patients 5 and 6) were tested as part of their clinical work-up in view of their specific family history.

Table 1.

Clinical findings in CMC patients with GOF-STAT1 mutation A267V.

	Pt 1	Pt 2	Pt 3	Pt 4	Pt 5	Pt 6
Age/gender	58/F	40/M	34/F	32/M	21/F	12/F
Candida infections
Oral	+	+	+	+	++	++
Genital	−	−	−	+	−	−
Nails +	++	+	+	+	+	−
Other infections
Skin
(abscesses/boils)	+	+++	+	+	−	−
Eczema	++	++	+	+++	−	−
Lungs
Bronchiectasis/COPD	−	++	−	−	+++	−
Autoimmunity
Hypothyroidism	++	−	−	+	−	−
Ocular
Keratitis	+	−	+++	+	−	−
Conjunctivitis	++	++	+	+	−	−
Other findings
Dental loss	++	+++	−	−	−	−
Reflux/diff swallowing	++	++	+++	+++	+++	−
Oral/oesoph. cancer	+	+	−	−	−	−

Pt = patient; F = female; M = male

Table 2.

Immunological findings in CMC patients with GOF-STAT1 mutation A267V.

	Pt 1	Pt 2	Pt 3	Pt 4	Pt 5	Pt 6
Age/gender	58/F	40/M	34/F	32/M	21/F	12/F	Normal ranges
Immunoglobulins (g/l)
IgG	19.6	11.1	11.9	11.4	11.0	9.0	5.8–15.4
IgA	3.21 ↑	1.46	4.14 ↑	4.12 ↑	2.91	1.24	0.64–2.97
IgM	3.62 ↑	1.54	1.71	0.98	1.38	1.17	0.71–2.30
IgG subclasses 1–4	normal	normal	normal	normal	normal	normal
C3/C4 complement	normal	normal	normal	normal	normal	normal
HIB abs	>9.0	6.5	0.4 ↓	1.5	>9	>9	1–20 mg/l
Pneumococcal abs	241	171	67	50	125	52	20–200 mg/l
Lymphocyte subsets (cells/μl)
CD3+ T cells	1751	1064	1268	1496	1393	1946	690–2540
CD4+ T cells	1127	690	955	874	701	879	410–1590
CD8+ T cells	521	304	250	513	597	859	190–1140
CD4/CD8 ratio	2.16	2.26	3.82 ↑	1.70	1.17	1.02	1.0–3.6
CD19+ B cells	307	362	348	392	144	709	90–660
CD 56+ NK cells	156	84	62	146	91	172	90–590
Lymphocyte proliferation
Mitogen PHA	normal	normal	normal	normal	normal	normal
Candida albicans	normal	normal	normal	normal	normal	normal
Other
Thyroid function	hypoth	normal	hypoth	normal	normal	normal
Thyroid abs (TPO)	>1300 ↑	74 ↑	55	162 ↑	50	8	0–59 ku/l
Antinuclear abs	negative	negative	negative	negative	negative	negative

Pt = patient; F = female; M = male; abs = antibodies; PHA = phytohaemagglutinin; TPO = thyroid peroxidise

Figure 4.

STAT1 gain-of-function in CMC patient 5. (a) STAT1 phosphorylation following stimulation with interferon (IFN) was assessed by flow cytometry. Whole blood from a healthy control and CMC patient 5 was stimulated with 10³IU/ml interferon (IFN)α (IFN-α2b Intron A, Merck Sharp & Dohme) for 30 minutes, cells were fixed, permeablised and stained with Alexa Fluor R 647 STAT1 (pY701) for pSTAT1 and CD3 Pacific Blue antibody for CD3 + T cells (all reagents from BD). Data were collected with a FACSCaliber (BD) and analysed with FlowJo software. Grey = healthy control; black = CMC patient; clear peaks = unstimulated cells; full peaks = IFNα stimulated cells. Median fluorescence intensity (MFI) is shown. (b) qRT-PCR of STAT1-dependent gene expression for CXCL10 and IRF1. In a healthy control and CMC patient 5, peripheral blood mononuclear cells were isolated and cultured in RPMI medium for 4 h with 1 × 10³IU/ml IFNα (IFN-α2b Intron A, Merck Sharp & Dohme), 1 µg/ml IFNγ (R&D Systems). Total RNA was purified using RNeasy Mini Kit (Qiagen) and reverse-transcribed into cDNA. Gene expression analysis for CXCL1o and IRF1 mRNA was performed with custom TaqMan gene expression assays (ABI). Gene expression was normalised to the housekeeping gene 18S rRNA. Data is expressed in the 2 − Ct format, where Ct = Ct (target) – Ct (18S). Results are for n = 3 replicates. Statistical significance was assessed by unpaired, two-tailed t test using Prism software. * = p > 0.05; ** = p > 0.01.

Discussion

It is now recognised that patients with CMCD, particularly those with the GOF-STAT1 mutation, have a broad clinical phenotype, significantly reduced life expectancy and an increased incidence of SCC.¹¹ Management of these patients always includes antifungal therapy to control mucocutaneous cutaneous candidiasis in spite of which SCC develops, indicating the need to consider urgent gastroscopies in the symptomatic patient as well as regular annual surveillance endoscopy with Lugol’s iodine chromoendoscopy to detect squamous dysplasia.

Unlike conventional oesophageal carcinoma, patients who develop oesophageal SCC on a background of CMCD present at a younger age. Delsing et al. reported a 25-year-old female who presented with dysphagia on a background of CMCD and GOF-STAT1 gene mutation, where the initial gastroscopy revealed only candidiasis, but the cytology confirmed malignant epithelial cells. A repeat gastroscopy 2 weeks later identified an irregular stenosis at 26 cm, and its histology was in keeping with SCC. Due to limited disease, the patient went on to have an oesophagectomy with reconstruction and colonic interposition with no further recurrence of oesophageal candidiasis or malignancy 20 years later.¹⁰

The pathogenic mechanisms leading to SCC in the presence of CMCD are not fully understood, but it is believed to be due to chronic inflammation caused by the infection, as well to candidial catalytic activity leading to the production of nitrosamines such as nitroso-N-methylbenzylamine (NBMA) which is carcinogenic.¹³

It is well known that the STAT1 gene is integral to innate immunity and mediates signalling of important inflammatory cytokines such as interferons (IFN) gamma (γ) and alpha (α). STAT1 is involved in mediating antibacterial, antiviral and antifungal immune responses, suppression of cell growth, and apoptosis as well as tumour genesis and tumour suppression.¹⁴ Some reports have found its levels to be reduced in transformed cancer cells, suggesting tumour suppressor properties, which is also supported by Zhang et al. who found that transfection of STAT1c into oesophageal squamous cell carcinoma cells resulted in apoptosis and cell cycle arrest, while the absence of STAT 1 was associated with poorer outcomes.¹⁵

Due to the high risk of oesophageal SCC in patients with CMCD, these patients should have an endoscopy if they have any upper gastrointestinal symptoms. They should also have regular surveillance endoscopy with chromoendoscopy using Lugol’s iodine or narrow band imaging to detect squamous dysplasia or early cancers. These patients present at a younger age compared to the conventional age for presentation of sporadic oesophageal SCC. Although the age at which this surveillance should start is not clear, it should be at least a decade earlier than the age of youngest member of the family diagnosed with oesophageal cancer. The intervals for surveillance endoscopy are also not certain, but at least annually or biannually. Squamous dysplasia of the oesophagus can now be treated endoscopically by endoscopic resection and radiofrequency ablation.¹⁶

In view of the fact that the underlying mutation has been identified as a GOF-STAT1, new therapeutic approaches should also be considered such as inhibition of STAT1 signalling by specific inhibitors of the JAK-STAT signalling pathway. Obviously, the potential deleterious effects of inhibiting a crucial inflammatory pathway must be weighed against potential benefits, but it is encouraging to know that sporadic case reports have reported significant benefits without major side-effects.¹⁷ However, this area still requires significant research.

Conclusion

In patients who present with recurrent oesophageal candidiasis we advise taking a thorough history, focusing on elements suggesting a PID such as age of onset, involvement of other body areas (skin and nail candidiasis), other infections, past medical history and family history of candidiasis. Additional testing should always exclude HIV infection as a cause of secondary immune deficiency. Consultation and/or referral to clinical immunology colleagues for further investigation and subsequent management of underlying PID is indicated.

CMC has a strong association with oral and oesophageal SCC, as such, these patients should be routinely monitored and investigated urgently if they present with upper gastrointestinal symptoms to detect early oesophageal cancer.

Footnotes

Conflict of interest

None declared.

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

References

Lilic

. Unravelling fungal immunity through primary immune deficiencies. Curr Opin Microbiol 2012; 15: 1–7.

Puel

Cypowyj

Marodi

. Inborn errors of human IL-17 immunity underlie chronic mucocutaneous candidiasis. J Allergy Clin Immunol 2012; 12: 616–622.

Takahashi

Nagata

Shimbo

. Long-term trends in esophageal candidiasis, prevalence and associated risk factors with or without HIV infection: lessons from an endoscopic study of 80,219 patients. PLoS One 2015; 10: e0133589–e0133589.

Baig

Rasheed

Subkowitz

. Severe esophageal candidiasis in an immunocompetent patient. Internet J Infect Dis 2005; 5: 1–4.

Puel

Natividad

Chrabieh

. Auto-antibodies to IL-17A, IL-17F and IL-22 in patients with chronic muco-cutaneous candidiasis and auto-immune polyendocrine syndrome type I. J Exp Med 2010; 207: 291–297.

Kisand

Bøe Wolff

Podkrajšek

. Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines. J Exp Med 2010; 207: 299–308.

Van de Veerdonk

Plantinga

Hoischen

. STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis. N Engl J Med 2011; 365: 54–61.

Liu

Okada

Kong

X-F

. Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J Exp Med 2011; 208: 1635–1648.

Zheng

van de Veerdonk

Crossland

. Gain-of-function STAT1 mutation in CMC patients impairs STAT3 activity which is reversed by STAT1 inhibition or enhancing acetylation. Eur J Immunol 2015; 45: 2834–2846.

10.

Delsing

Bleeker-Rovers

van de Veerdonk

. Association of oesophageal candidiasis and squamous cell carcinoma. Med Mycol Case Rep 2012; 1: 5–8.

11.

Toubiana

Okada

Hiller

. STAT1 gain of function mutations underlie an unexpectedly broad clinical phenotype: an international survey of 274 patients. Blood 2016; 127: 3154–3164.

12.

Smeekens

Plantinga

van de Veerdonk

. STAT1 hyperphosphorylation and defective IL12R/IL23R signaling underlie defective immunity in autosomal dominant chronic mucocutaneous candidiasis. PLoS One 2011; 6: e29248–e29248.

13.

Bakri

Hussaini

Holems

. Revisiting the association between candida infection and carcinoma, particularly oral squamous cell carcinoma. J Oral Microbiol 2010; 2: 5780–5786.

14.

Meissl K, Macho-Maschler S, Muller M, et al. The good and the bad faces of STAT1 in solid tumours. Cytokine. Epub ahead of print 26 November 2015. DOI: 10.1016/j.cyto.2015.11.011.

15.

Zhang

Molavi

. The clinical and biological significance of STAT1 in esophageal squamous cell carcinoma. BMC Cancer 2014; 14: 791–791.

16.

Haidry

Butt

Dunn

. Radiofrequency ablation for early squamous neoplasia: outcomes from United Kingdom registry. World J Gastroenterol 2013; 19: 6011–6019.

17.

Higgins

Al-Shehri

McAleer

. Successful treatment of a patient with chronic mucocutaneous candidiasis due to a gain-of-function STAT1 mutation with the JAK1/2 inhibitor ruxolitinib. JACI 2015; 135: 551–553.